This company has been acquired
AVEO Pharmaceuticals Management
Management criteria checks 3/4
Key information
Michael Bailey
Chief executive officer
US$2.9m
Total compensation
CEO salary percentage | 20.0% |
CEO tenure | 8yrs |
CEO ownership | 1.0% |
Management average tenure | 2.7yrs |
Board average tenure | 8yrs |
Recent management updates
Recent updates
AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash
Oct 18Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money
Oct 04A Current Assessment On AVEO Pharmaceuticals
Aug 15Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt
Jun 21AVEO Pharmaceuticals Is Primed For A Breakout
May 24Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results
Mar 17AVEO Pharmaceuticals: Finally Ready To Reboot
Mar 09AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 03AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 23AVEO Pharmaceuticals: Sticking To The Plan
Oct 29AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
Jul 24AVEO Oncology: Time To Be Patient
Jun 07AVEO outlines 2021 outlook; initiates Phase 1 trial for cancer complication
Jan 07AVEO Oncology: Managing A Position Ahead Of Tivozanib's PDUFA
Dec 27CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2022 | n/a | n/a | -US$29m |
Jun 30 2022 | n/a | n/a | -US$36m |
Mar 31 2022 | n/a | n/a | -US$41m |
Dec 31 2021 | US$3m | US$590k | -US$53m |
Sep 30 2021 | n/a | n/a | -US$58m |
Jun 30 2021 | n/a | n/a | -US$56m |
Mar 31 2021 | n/a | n/a | -US$49m |
Dec 31 2020 | US$2m | US$565k | -US$36m |
Sep 30 2020 | n/a | n/a | -US$29m |
Jun 30 2020 | n/a | n/a | -US$4m |
Mar 31 2020 | n/a | n/a | US$452k |
Dec 31 2019 | US$2m | US$528k | US$9m |
Sep 30 2019 | n/a | n/a | US$36m |
Jun 30 2019 | n/a | n/a | -US$3m |
Mar 31 2019 | n/a | n/a | US$4m |
Dec 31 2018 | US$3m | US$528k | -US$5m |
Sep 30 2018 | n/a | n/a | -US$24m |
Jun 30 2018 | n/a | n/a | -US$28m |
Mar 31 2018 | n/a | n/a | -US$65m |
Dec 31 2017 | US$1m | US$480k | -US$65m |
Sep 30 2017 | n/a | n/a | -US$74m |
Jun 30 2017 | n/a | n/a | -US$53m |
Mar 31 2017 | n/a | n/a | -US$28m |
Dec 31 2016 | US$1m | US$444k | -US$27m |
Compensation vs Market: Michael's total compensation ($USD2.94M) is about average for companies of similar size in the US market ($USD2.52M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Bailey (57 yo)
8yrs
Tenure
US$2,943,905
Compensation
Mr. Michael P. Bailey serves as an Independent Chairman at IMV Inc. since May 01, 2022 and has been its Independent Director since July 20, 2020. He has been Chief Executive Officer and President of AVEO P...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 8yrs | US$2.94m | 0.98% $ 5.1m | |
Chief Financial Officer | 3yrs | US$1.24m | 0% $ 0 | |
Chief Commercial Officer | no data | US$1.25m | 0.038% $ 200.0k | |
Chief Operating Officer | 1.1yrs | no data | 0% $ 0 | |
VP of Legal & Corporate Secretary | 2yrs | no data | no data | |
Senior Vice President of Marketing | 3.2yrs | no data | no data | |
Vice President of Sales | 2.3yrs | no data | no data | |
Vice President of Human Resources | 2.3yrs | no data | no data | |
VP of Finance & Treasurer | 7yrs | no data | no data |
2.7yrs
Average Tenure
54.5yo
Average Age
Experienced Management: AVEO's management team is considered experienced (2.7 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 8yrs | US$2.94m | 0.98% $ 5.1m | |
Independent Director | 20.8yrs | US$127.61k | 0.12% $ 627.6k | |
Independent Chairman | 15.1yrs | US$158.73k | 0.0011% $ 5.6k | |
Member of Scientific Advisory Board | no data | US$3.00k | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.9yrs | US$120.61k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.2yrs | US$126.84k | 0% $ 0 |
8.0yrs
Average Tenure
63yo
Average Age
Experienced Board: AVEO's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/01/21 21:25 |
End of Day Share Price | 2023/01/19 00:00 |
Earnings | 2022/09/30 |
Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AVEO Pharmaceuticals, Inc. is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Madhu Kumar | Baird |
James Birchenough | BMO Capital Markets Equity Research |
James Birchenough | BMO Capital Markets U.S. (Historical) |